Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.
Tyrosine kinase oncogenes are formed as a result of mutations that induce constitutive kinase activity. Many of these tyrosine kinase oncogenes that are derived from genes, such as c-Abl, c-Fes, Flt3, c-Fms, c-Kit and PDGFRbeta, that are normally involved in the regulation of hematopoiesis or hematopoietic cell function. Despite differences in structure, normal function, and subcellular location, many of the tyrosine kinase oncogenes signal through the same pathways, and typically enhance proliferation and prolong viability. They represent excellent potential drug targets, and it is likely that additional mutations will be identified in other kinases, their immediate downstream targets, or in proteins regulating their function.
Scheijen
Blanca
B
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts, MA 02115, USA.
Griffin
James D
JD
D000818:Animals; D019337:Hematologic Neoplasms / Q000201:enzymology*; D006410:Hematopoiesis / Q000235:genetics* / Q000502:physiology*; D006801:Humans; D007938:Leukemia / Q000201:enzymology* / Q000235:genetics*; D008223:Lymphoma / Q000201:enzymology* / Q000235:genetics*; D008954:Models, Biological; D021381:Protein Transport; D011505:Protein-Tyrosine Kinases / Q000235:genetics*; D015398:Signal Transduction
D011505:Protein-Tyrosine Kinases